In an emergency such as a pandemic outbreak or last year’s vaccine shortage, the influenza vaccine could be produced twice as fast using cell cultures in existing biopharmaceutical manufacturing facilities, according to Henry Wang, a University of Michigan professor of biomedical and chemical engineering, Wang and graduate student Lyle Lash, speaking at the 229th American Chemical Society National Meeting March 13-17, will propose a system for retrofitting existing biopharmaceutical buildings to produce the flu vaccine using cell cultures. The plan would require proper government and industry support and some advanced planning and training. Wang and Lash first did a case study of traditional vaccine manufacturing, where the virus is injected and incubated in a chicken egg, killed and extracted, then bottled and sold. The process takes more than four months. Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.